If you are involved in academic multinational trials in Europe as a sponsor, an investigational site, a CRO, a CTU, or involved in the development of national procedures/templates for harmonisation of CTA, we have developed this survey for you! Working within the ERA4Health Partnership, the ultimate goal is the development of a harmonised Clinical Trial Agreement (CTA) to facilitate the conduct of academic multinational clinical trials in Europe. Your invaluable input will help us: • Collect information about the existing CTA templates/models across the EU • Get a broader understanding of the issues encountered by the academic sponsors of multinational clinical trials and other relevant actors when dealing and negotiating CTAs in the context of multinational clinical trials, • Identify the negotiable and non-negotiable national specificities (e.g. provisions mandatory by law) of CTAs • Find a shared understanding of how an EU CTA template should look like so that it can be used as a model in the context of academic multinational clinical trials Interested in contributing to this work? Answer here: https://lnkd.in/e5pSZKX5 #ClinicalTrials, #CTA, #harmonisation CZECRIN, Infrastructure F-CRIN, KKS-Netzwerk e. V., HRB National Clinical Trials Office (NCTO), NorCRIN, PtCRIN Portuguese Clinical Research Infrastructure Network, SLOVACRIN, Spanish Clinical Research Network (SCReN), Swiss Clinical Trial Organisation, European Medicines Agency
ECRIN (European Clinical Research Infrastructure Network)’s Post
More Relevant Posts
-
ECRIN is there to support requests for information from investigators and sponsors in our member countries. 💬 The acquisition of general information and support in the planning of a clinical study is of utmost importance in understanding the regulatory landscape, identifying funding opportunities and correctly defining the scope, roles and responsibilities of the work to include in the funding application. This assistance ensures initial clinical research questions become an operational reality. 🌟 👉 Learn about this and our full-service offer in our updated clinical trials brochure: https://lnkd.in/gfWwcqby
-
-
The EJP-RD project has just come to an end. Learn about ECRIN’s role in this project and some of the exciting ways ECRIN supports the rare disease community. 🌈 Our Head of Capacity Projects and rare diseases expert, Marta del Álamo sheds some light on this subject in the dedicated annual report interview. 💡 👉 View the full interview today: https://lnkd.in/ezA5xyXR
-
-
ECRIN's Director General, Jacques Demotes sat down to discuss investigator initiated clinical trials in a special edition of the ERA4Health newsletter. He discusses what they are, funding opportunities, the advantages of ensuring that they can be carried out across borders and how ERA4Health is looking to support them. Take a minute and peruse the article ⬇
📢 Flash Newsletter: Special Edition on Investigator-Initiated Clinical Trials (IICS)! 📢 🌟 Don't miss our exclusive interview with Jacques Demotes Mainard, Director General of ECRIN (European Clinical Research Infrastructure Network)! 🌟 📅 Join us and keep up to date with the latest developments in the world of clinical research. https://lnkd.in/dV65ridi
-
What does an ECRIN coordinating European Correspondent do? 🤔 We sat down with Dr. Linda Stöhr & Neshat Chareh, PhD, our German EuCos, to learn more about this role and how ECRIN supports the KKS-Netzwerk e. V. in Germany. 🤝 👉 Take a minute and read the interview to get the answers to these questions and more: https://lnkd.in/dPyq-n-f
-
-
How does ECRIN help Sponsors and Investigators conduct multinational clinical studies? 👇 Throughout the whole process our staff and notably European Correspondents provide Expertise and Overarching support for the maturation and execution of investigator and sponsors’ ideas. 💡 They ensure a solid understanding of the different roles and responsibilities associated with the different steps and work to define a clear task distribution. 📝 👉 Learn about this and our full service offer in our updated clinical trials brochure: https://lnkd.in/gfWwcqby
-
-
🚨 Attention cancer researchers! We’re excited to announce free services through the canSERV open calls, available until August 28th 2024. ⏳ 🌟 One of the current call focuses on Innovative approaches to research and clinical trials for improved treatment outcomes, with 2 topics on the spotlight: - 𝐄𝐧𝐬𝐮𝐫𝐞 𝐨𝐩𝐭𝐢𝐦𝐚𝐥 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐮𝐭𝐜𝐨𝐦𝐞𝐬: tailoring research for different age groups (e.g., paediatric and elderly patients) - 𝐃𝐞𝐬𝐢𝐠𝐧𝐢𝐧𝐠 𝐢𝐦𝐩𝐫𝐨𝐯𝐞𝐝 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥𝐬 𝐟𝐨𝐫 𝐝𝐢𝐯𝐞𝐫𝐬𝐞 𝐩𝐨𝐩𝐮𝐥𝐚𝐭𝐢𝐨𝐧𝐬: for broader patient representation from EU and matched control groups. In this call, ECRIN offers expert guidance for the design of complex multinational trials, and a secure GDPR-compliant data storage for your research through the crDSR (clinical research data sharing repository). 🤲 👉 Seize this opportunity and apply now: https://lnkd.in/dEW3dnrN ✉ Contact us to learn more about ECRIN services: https://ecrin.org/contact #OpenCall #ResearchOpportunities #CancerResearch
-
The highlights of the past five years of the European Joint Programme on Rare Diseases (EJP RD) programme are included in a new article. 🌟 Titled "The European joint programme on rare diseases: building the rare diseases research ecosystem" this article published on the Rare Diseases and Orphan Drugs Journal delves into our collective achievements and ongoing efforts to foster a robust research environment for rare diseases. 🚀 Through collaborative projects, innovative research, and dedicated support for the rare disease community, we continue to make strides in understanding and addressing these unique health challenges. Read the full article here: https://lnkd.in/eHXJA_6g
The European joint programme on rare diseases: building the rare diseases research ecosystem
oaepublish.com
-
Very exciting announcement from the ERA4Health Partnership: a new funding opportunity for Investigator Initiated Clinical Studies coming this fall. Stay tuned for details on the topic to be addressed.
Today, Wednesday 3rd of July, our consortium celebrates a Workshop aimed to refining the topic of ERA4Health Pilot Call on Investigator-Initiated Clinical Studies (IICS). This Partnership brings the opportunity to increase European transnational collaborative research funding by creating a funding body for joint programming in priority areas addressing European public health needs. Multinational IICS play a critical role in addressing societal issues often overlooked by industry players, emphasizing their high societal value. However, despite their significance, these studies often face challenges due to the absence of optimal funding mechanisms. To address this issue, the ERA4Health partnership has developed a framework and is planning to launch its first IICS-dedicated call by November of this year. This workshop aims to refining the call topic and discussing specific issues with experts and funding agencies to encourage and enable transnational collaboration between clinical/public health research. Instituto de Salud Carlos III FICYT ECRIN (European Clinical Research Infrastructure Network) Health Research Board (HRB) Ministry of Health Israel DLR Projektträger AICIB - Agência de Investigação Clínica e Inovação Biomédica Research Council of Lithuania | Lietuvos mokslo taryba The National Centre for Research and Development
-
-
Congratulations to the TTV-GUIDE TX trial team! Today they announced that they have closed recruitment for the trial.
And it's a wrap!! 🥳 We are very happy and proud to announce that we have officially finalised the recruitment for our #TTVGuide trial. This means that no further patients can be included in the trial. Randomisations, however, are not affected. Patients who are already in the screening phase can still be randomised. Also, as the graphic hereunder shows, 11 out of 13 sites have already reached their recruitment target!! 🙌 📋 What’s our trial about you may ask? We aim to prove that low levels of the Torque Teno Virus (#TTV) in the blood might flag a risk for organ rejection in kidney transplants, while a high TTV load could signal infection. 🤔 Why does it matter? We're aiming to hand healthcare providers a clever tool – a so called “immune-meter”. By monitoring TTV levels in the blood, we hope to offer a clear picture of a #transplant recipient's immune system response. It's an important trial for the future of kidney transplantation and if we are successful, ultimately for many other fields of medicine too! Stay tuned and follow us for updates on the trial!! #horizon2020 #euproject #MedicalAdvancements #HealthcareInnovation #ClinicalTrials
-
